Cornell Pochily Investment Advisors Inc. Sells 377 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Cornell Pochily Investment Advisors Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,217 shares of the biopharmaceutical company’s stock after selling 377 shares during the period. Cornell Pochily Investment Advisors Inc.’s holdings in Gilead Sciences were worth $944,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bellevue Group AG lifted its position in Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after acquiring an additional 7,093 shares in the last quarter. Quantinno Capital Management LP increased its holdings in Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after buying an additional 48,910 shares during the last quarter. IRON Financial LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $830,000. Capital Investment Advisors LLC lifted its stake in Gilead Sciences by 2.6% in the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after purchasing an additional 9,791 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Gilead Sciences by 12.9% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company’s stock worth $27,081,000 after purchasing an additional 36,895 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Robert W. Baird raised their price objective on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. UBS Group increased their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Finally, Morgan Stanley upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $93.07 on Monday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The firm has a market capitalization of $115.99 billion, a price-to-earnings ratio of 1,034.11, a P/E/G ratio of 1.31 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm’s 50 day simple moving average is $91.74 and its 200 day simple moving average is $85.09.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the company posted $2.29 EPS. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 456,234 shares of company stock worth $42,130,461. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.